CoChat

LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations.

Yang, James Chih-Hsin, Schuler, Martin H., Yamamoto, Nobuyuki, O'Byrne, Kenneth John, Hirsh, Vera, Mok, Tony, Geater, Sarayut Lucien, Orlov, Sergey V, Tsai, Chun-Ming, Boyer, Michael J., Su, Wu-Chou, Bennouna, Jaafar, Kato, Terufumi, Gorbunova, Vera, Lee, Ki Hyeong, Shah, Riyaz N.H., Massey, Dan, Lorence, Robert M., Shahidi, Mehdi, Sequist, Lecia V. · 2012 · Journal of Clinical Oncology
Cited by 67

The DOI matches its Crossref record.

Abstract

LBA7500 Background: Afatinib (A) is a selective, orally bioavailable, irreversible ErbB family blocker of EGFR (ErbB1), HER2 (ErbB2), and ErbB4. This global study investigated the efficacy and safety of A compared with pemetrexed/cisplatin (PC) in pts with EGFR mutation positive advanced lung adenocarcinoma. Methods: Following central testing for EGFR mutations (companion diagnostic TheraScreen EGFR RGQ PCR kit), 345 pts (stage IIIB/IV, PS 0–1, chemo-naive) were randomized 2:1 (A: 230; PC: 115) to daily A 40 mg or iv PC (500 mg/m 2 + 75 mg/m 2 q21 days up to 6 cycles). Primary endpoint was progression-free survival (PFS) by central independent review. Results: Baseline characteristics were balanced in both arms: median age, 61 y; female, 65%; Asian, 72%; never-smoker, 68%; Del19, 49%; L858R, 40%; other mutations, 11%. Treatment with A led to a significantly prolonged PFS vs PC (median 11.1 vs 6.9 mos; HR 0.58 [0.43–0.78]; p=0.0004). In 308 pts with common mutations (Del19/L858R), median PFS was 13.6 vs 6.9 mos, respectively (HR=0.47 [0.34–0.65]; p<0.0001). Objective response rate was significantly higher with A (56% vs 23%; p<0.0001). Significant delay in time to deterioration of cancer-related symptoms of cough (HR=0.60, p=0.0072) and dyspnea (HR=0.68, p=0.0145) was seen with A vs PC. Most common drug-related adverse events (AEs) were diarrhea (95%), rash (62%) and paronychia (57%) with A, and nausea (66%), decreased appetite (53%) and vomiting (42%) with PC. Drug-related AEs led to discontinuation in 8% (A; 1% due to diarrhea) and 12% of pts (PC). Conclusions: LUX-Lung 3 is the largest prospective trial in EGFR mutation positive lung cancer and the first study using pemetrexed/cisplatin as a comparator. Treatment with afatinib significantly prolonged PFS compared to PC, with significant improvements in secondary endpoints. AEs with afatinib were manageable, with a low discontinuation rate. With 4.2 mos PFS improvement in the overall population and 6.7 mos in pts with common mutations, afatinib is a clinically relevant first-line treatment option.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2012.30.18_suppl.lba7500

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 67

Metadata

Authors
Yang, J. C.-H., Schuler, M. H., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T., Geater, S. L., Orlov, S. V., Tsai, C.-M., Boyer, M. J., Su, W.-C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K. H., Shah, R. N. H., Massey, D., Lorence, R. M., Shahidi, M., & Sequist, L. V.
Venue
Journal of Clinical Oncology
Published
2012-06-20
Volume
30
Issue
18_suppl
Pages
LBA7500-LBA7500
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W4253465303
Cited by
67
References
0
Type
conference abstract
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. https://app.cochat.ai/papers/10.1200/jco.2012.30.18_suppl.lba7500
The paper
Yang, J. C.-H., Schuler, M. H., Yamamoto, N., O'Byrne, K. J., Hirsh, V., Mok, T., Geater, S. L., Orlov, S. V., Tsai, C.-M., Boyer, M. J., Su, W.-C., Bennouna, J., Kato, T., Gorbunova, V., Lee, K. H., Shah, R. N. H., Massey, D., Lorence, R. M., Shahidi, M., & Sequist, L. V. (2012). LUX-Lung 3: A randomized, open-label, phase III study of afatinib versus pemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.30.18_suppl.lba7500

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.